Bupivacaine Hydrochloride NDC 71351-022

NDC codes

FDA NDC Directory

Product NDC (as listed)71351-022Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71351-0022Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71351-022-10	71351002210	10 AMPULE in 1 PACKAGE (71351-022-10) / 2 mL in 1 AMPULE (71351-022-02)Marketed from Feb 23, 2023
71351-022-50	71351002250	50 AMPULE in 1 PACKAGE (71351-022-50) / 2 mL in 1 AMPULE (71351-022-02)Marketed from Oct 31, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Bupivacaine Hydrochloride
Generic name (nonproprietary): bupivacaine hydrochloride
Active ingredients: Bupivacaine hydrochloride — 7.5 mg/mL
Dosage form: Injection
Route: Subarachnoid
Labeler: Brookfield Pharmaceuticals, LLC.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212822
Marketing start: Oct 31, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Amides (Chemical structure)Local Anesthesia (Physiologic effect)
Identifiers: Product ID 71351-022_484033d6-ca7d-f0fd-e063-6294a90a7890SPL ID 484033d6-ca7d-f0fd-e063-6294a90a7890SPL set ID e8b32972-6984-4f1c-e053-2995a90a3277RxCUI 1724784UNII 7TQO7W3VT8UPC 0371351022509, 0371351022028, 0371351022103
Pharmacologic class: Amide Local Anesthetic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N471351002210 followed by a unit qualifier and the quantity

Package 71351-0022-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 13, 2026.

Indications (excerpt from the label)

Bupivacaine Hydrochloride in Dextrose Injection, USP is indicated for subarachnoid injection in adults for the production of subarachnoid block (spinal anesthesia).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212822

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212822
Product	Strength	Form · route	Labeler	Product NDC
Bupivacaine Hydrochloride	Bupivacaine hydrochloride 7.5 mg/mL	InjectionSubarachnoid	Huons Co., Ltd.	73293-0002